Objectives: Antimicrobial susceptibility data for Chlamydia trachomatis are lacking. Methodologies for susceptibility testing in C. trachomatis are not well-defined, standardized or performed routinely owing to its intracellular growth requirements. We sought to develop an assay for the in vitro susceptibility testing of C. trachomatis isolates from two patient cohorts with different clinical outcomes.
Introduction
Chlamydia trachomatis is the most prevalent bacterial sexually transmitted infection worldwide with 202546 diagnoses in England in 2016. 1 Current first-line recommended treatment regimens for uncomplicated infection are 1 g stat azithromycin, or 100 mg doxycycline twice a day for 7 days. 2 Whilst the efficacy of these treatments is considered to be extremely high, 3 ,4 treatment failure with 1 g stat azithromycin has been demonstrated in C. trachomatis-positive men with non-gonococcal urethritis and rectal chlamydia and in women not at risk of re-infection. [5] [6] [7] Further reports of treatment failure have been described in patients where the risk of re-infection is low. [8] [9] [10] [11] [12] [13] [14] [15] There are a number of possible reasons why patients may remain positive for chlamydia after treatment: non-adherence to the treatment regimen; re-infection from a new or untreated partner; inadequate exposure to the antimicrobial as a result of host pharmacokinetics or short duration of treatment, 16 and heterotypic or homotypic antimicrobial resistance. Heterotypic resistance, also known as phenotypic switching, occurs when a heterogeneous population of both resistant and susceptible organisms replicate from a single predecessor. 7 It is not genetically inherited but is a result of adaptations by the bacteria to make them less susceptible to the antimicrobial e.g. induction of slow-growing, non-replicative or persistent forms in the presence of antibiotic, which revert to replicating forms once the antibiotic pressure has been removed, resulting in a relapse in infection. Homotypic antimicrobial resistance is, in contrast, genetically inherited.
At high bacterial loads, for instance as found in patients with symptoms of urethritis, 17 C. trachomatis has been shown to exhibit heterotypic resistance. 18, 19 Confirmed phenotypic decreased susceptibility to antimicrobials of clinical significance has been reported rarely in C. trachomatis. 9, 11, 20, 21 Stable genotypic resistance to antimicrobials in clinical practice has yet to be documented in human urogenital C. trachomatis infection. 16 However very little is known about the susceptibility profiles of circulating strains because antimicrobial susceptibility assays are not routinely performed and the methodology is neither standardized nor well defined. 7, 18, 22 We describe the development of a robust antimicrobial susceptibility testing methodology (adapted from Storm et al.
23
), and report susceptibility data for azithromycin and doxycycline for a cohort of C. trachomatis isolates from patients who were persistently infected with C. trachomatis. Susceptibility data are also presented for C. trachomatis isolates from a group of control patients who were C. trachomatis-positive at initial presentation and were then confirmed to have been treated successfully.
Methods

Patient recruitment
As reported previously, 24 patients with persistent C. trachomatis infections were recruited from sexual health clinics across England and Wales.
Patients were deemed to have a persistent infection if they had tested positive at least twice by a C. trachomatis-specific assay (e.g. a nucleic acid amplification test, NAAT), had fully adhered to the prescribed treatment regimens in line with current guidelines 2 (including any abstinence periods) and were assessed to be at low risk of re-infection. Risk of re-infection was categorized using self-declared sexual contact behaviour in the time since initial diagnosis, reported via a clinician-completed questionnaire. Patients were considered at low risk of re-infection following treatment if they had: (i) no sexual contact; (ii) protected sexual contact only; or (iii) unprotected sexual contact with a partner who had not tested positive or who had tested positive, but had been treated. These groups were designated categories 1, 2 and 3 respectively. Clinical data collected for some of the patients in this report were reported previously. 24 Control isolates were collected from patients who had been treated for C. trachomatis infection in line with current UK guidelines 2 and had a negative test-of-cure by NAAT at least 30 days later.
Ethics approval
Patients with persistent infections were referred as part of an enhanced surveillance programme and therefore ethics approval was not sought or required. Public Health England has permission to handle these data under the Health Service (Control of Patient Information) regulation 2002, overseen by the Confidentiality Advisory Group. Control patients were recruited through a sexual health clinic, ethics reference number 13/WM/0088.
Culture methods
Stock inoculum culture
Clinical specimens [persistently infected group: 6 specimens from male patients (5 urethral swabs and 1 rectal swab) and 5 specimens from female patients (4 cervical swabs and 1 urethral swab); successfully treated group: 2 specimens from male patients (1 urethral swab and 1 swab from an unknown site) and 11 specimens from female patients (3 cervical swabs, 8 self-collected vaginal swabs] were inoculated onto confluent McCoy cell monolayers in shell vials. Shell vials were centrifuged at 2300 g for 1 h at 35 C and were then incubated for 4 h at 35 C in 5% CO 2 . The inoculum was then aspirated and the infected monolayer was overlaid with DMEM (Gibco, Hemel Hempstead, UK) supplemented with 10% fetal bovine serum (Gibco), 200 mM L-glutamine (Sigma-Aldrich, Gillingham, UK), 1 mg/L cycloheximide (Sigma-Aldrich), 100 mg/L gentamicin (Gibco), 25 U/mL nystatin (Sigma) and 100 mg/L vancomycin (Sigma-Aldrich). Shell vials were incubated for 48 h at 35 C in 5% CO 2 to produce a stock inoculum of each strain for antibiotic susceptibility testing assays. Inclusion forming units (IFU) were visualized after staining with the MicroTrak V R Chlamydia trachomatis culture confirmation test (Trinity Biotech, Newmarket, UK).
Susceptibility assays
MICs of azithromycin and doxycycline were determined as follows; confluent McCoy cell monolayers in 48-well plates were overlaid with the stock inoculum of each strain (10 3 -10 5 IFU per well), plates were centrifuged for 1 h at 1350 g and 35 C and were then incubated at 35 C, 5% CO 2 for 4 h to facilitate infection. Wells were aspirated and overlaid with two-fold serial dilutions of antimicrobial (0.125-2 mg/L azithromycin or 0.064-1 mg/L doxycycline) in supplemented DMEM (as above). An antimicrobial-free control was included for each strain to allow identification of assay failure. Owing to the lack of known azithromycin-or doxycycline-resistant control isolates of C. trachomatis, a susceptible control C. trachomatis isolate (from a successfully treated patient, isolate 314) was used in the azithromycin assays, and the tetracycline-resistant C. suis strain R19 25 was used in the doxycycline assays. Plates were then incubated for 48 h at 35 C in 5% CO 2 .
RNA extractions and cDNA generation
The RNeasy Plus Mini Kit (QIAGEN, Manchester, UK) was used as per the manufacturer's instructions to extract total RNA from aliquots of culture media collected from each antibiotic concentration and negative control at varying stages during the susceptibility assay, namely the initial inoculum (P0) and after the 48 h incubation with antimicrobial (P1). cDNA was reverse transcribed from the total RNA (2 lL per reaction) using the Quantitect reverse transcription kit (QIAGEN) as per manufacturer's instructions. This kit includes a step for removing contaminating genomic DNA negating the need for a separate DNaseI digestion.
Real time-PCR to detect transcription and interpretation of MIC endpoint
cDNA was used as template for real time PCR (RT-PCR) on the RotorGene (QIAGEN) platform (primer and probe sequences in Table 1 ) to quantify the C. trachomatis transcripts and allow assignment of an MIC of each antimicrobial for each strain. The method described by Storm et al. 23 was modified to facilitate use of an L2 internal control, prepared in-house, for transcript quantification. In place of the omp2 gene target, a predicted virulence factor on the C. trachomatis cryptic plasmid was used as the chlamydia-specific target. 26 The McCoy cell b-actin gene (inhibition control) and the C. suis R19 23S rRNA gene were detected qualitatively only where appropriate. To increase assay sensitivity each target was run as a separate reaction.
Twenty-five microlitre reactions were prepared for each target in HotStarTaq master mix (QIAGEN). Primer and probe sequences can be Susceptibility testing of Chlamydia trachomatis JAC found in Table 1 A standard curve was generated using a previously quantified C. trachomatis L2 cryptic plasmid positive control on each C. trachomatis-specific PCR run to allow quantification of transcripts. As described by Storm et al. 23 the MIC was assigned to the lowest antimicrobial concentration where a 95% reduction in transcription was observed after a passage in the presence of antimicrobial (P1) in comparison with the initial inoculum (P0) for each strain. RT-PCR was used only for MIC assignment to negate subjectivity of immunofluorescent staining interpretation.
Statistical analysis
Geometric means of the azithromycin and doxycycline MICs were calculated and linear regression was used to analyse the relationship between the MICs and the different patient groups. As absolute MICs were not available for a number of isolates (i.e. MICs were or ) then MIC values a doubling dilution above or below the recorded MIC were used (e.g. 0.064 mg/L was analysed as 0.032 mg/L and 1 mg/L was analysed as 2 mg/L). Fisher's exact test was used to compare azithromycin MICs 0.25 mg/L versus MICs .0.25 mg/L and doxycycline MICs 0.064 mg/L versus MICs .0.064 mg/L in the persistently infected and successfully treated patient groups respectively. Results for both tests were deemed significant if the P value was 0.05.
Results
Isolate retrieval
Isolates were retrieved from 11 patients with persistent C. trachomatis infections that met the inclusion criteria outlined previously (five in category 1, two in category 2 and four in category 3). In addition, isolates were retrieved from 13 control patients with linked negative test-of-cure samples.
MIC data
Azithromycin MICs were 0.25 mg/L for 81.8% (9/11) of the isolates from patients with persistent infections and for 100% (13/13) of isolates from the successfully treated control patients (Tables 2 and 3 ). The azithromycin geometric mean MICs were 0.127 mg/L and 0.071 mg/L for isolates from the persistently positive group and the successfully treated patient group, respectively. Azithromycin MICs for two isolates (18.2%) in the persistently infected group were 2 mg/L and 0.5 mg/L (Tables 2 and 3) . No difference (Fisher's exact test, P "0.3; linear regression P "0.1) was observed between the azithromycin MICs for isolates from the persistently infected patients compared with those for isolates from the successfully treated patients. The MICs of doxycycline for the isolates from the successfully treated patient group were significantly lower than MICs for isolates from the persistently infected patient group (Fisher's exact test, P "0.006); doxycycline MICs for 7/11 (63.6%) isolates from patients with persistent infections were 0.125 mg/L, and for the remaining four isolates (36.4%) were 1 mg/L. The doxycycline MICs for most (7/13, 53.9%) isolates in the successfully treated group were 0.064 mg/L, at least twofold lower than the lowest MICs for isolates from the treatment failure group. The doxycycline MICs for the five remaining isolates from the successfully treated group were 0.125 mg/L (three isolates), 0.25 mg/L (one isolate) and 1 mg/L (three isolates) ( Table 2) . These patients were all treated with azithromycin 1 g only. The doxycycline geometric mean MICs were 0.322 mg/L and 0.097 mg/L for isolates from the persistently positive group and the successfully treated patient group, respectively (P"0.032).
Assay reproducibility
To investigate the robustness of the susceptibility testing methodology, 11 (45.8%) isolates chosen at random [eight (8/11, 72.7%) from the persistently infected and three (3/13, 23.1%) from the successfully treated patient groups] were repeat tested on the azithromycin assay and the MICs from both assay runs compared. All (11/11, 100%) repeat MICs were in complete agreement with initial testing. Thirteen (54.2%) isolates chosen at random [five (5/11, 45.5%) from the persistently infected and eight (8/13, 61.5%) from the successfully treated patient groups] were repeat tested on the doxycycline assay. Twelve (12/13, 92.3%) of the repeat MICs were in agreement with the initial MIC data. For one isolate in the successfully treated group the repeat MIC of doxycycline (0.064 mg/L) was at least four-fold (two dilution steps) lower than the initial MIC (0.25 mg/L). During initial validation of the assays the range of antimicrobial concentrations tested were altered as considered appropriate based on the MICs obtained. The initial assay for this isolate had 
Discussion
We have adapted and further developed an assay for phenotypic in vitro antimicrobial susceptibility testing of C. trachomatis. The assay was used to test clinical isolates sourced from two distinct patient groups, one with persistent C. trachomatis infections and the other with C. trachomatis infections successfully treated following first-line recommended therapy (i.e. 1 g stat azithromycin). Clinical isolates from both groups were assayed against azithromycin and doxycycline. The assay methodology produced reproducible MICs of both antimicrobials when isolates were retested, with 95.8% of isolates giving identical MICs. The exception was an MIC obtained in a 'failed' repeat assay that was at least four-fold lower than for the initial assay. MICs of doxycycline for the isolates from patients who had persistent infections were significantly higher than for isolates from successfully treated patients. A number of the patients in the Tetracycline-resistant C. suis strain R19. 25 Susceptibility testing of Chlamydia trachomatis JAC persistently infected group had been treated with doxycycline in addition to azithromycin ( Table 2 ). The doxycycline MICs for these isolates varied from 0.125 mg/L, which is comparable to the majority of the MICs for isolates from the successfully treated group, to .1 mg/L which is significantly less susceptible. However, the doxycycline MICs for two isolates in the successfully treated group were also 1 mg/L and neither of these patients was treated with doxycycline regimens. The significance of these raised MICs is unclear.
There did not appear to be a difference between the MICs of azithromycin for isolates from the two patient groups. Indeed, whilst the majority of patients in the persistently infected group were treated at least twice with 1 g azithromycin stat regimens ( Table 2 ) the MICs for the isolates from these patients were mostly within a two-fold dilution compared with the MICs for the isolates from the successfully treated patients and the 'susceptible' control strain, 314. There were two isolates in the persistently infected group with azithromycin MICs at least two dilutions higher than control strain 314 and the successfully treated patient group. Interestingly, both of these patients had only been treated once with 1 g azithromycin stat regimens. Overall, this suggests that the antibiotic pressure exerted by re-treatment with the same antibiotic did not select for increased MICs (reduced susceptibility) in these isolates. It may be hypothesized that heterotypic resistance induced in vivo may account for the similarity of MIC in vitro, but the difference in clinical outcome seen with these patients (if reinfection can truly be excluded, as asserted).
What is clear from the data presented is that much further work is needed to understand the relevance of the MICs obtained from both patients who resolve infection after treatment with first-line therapies and from patients who remain infected. In vitro susceptibility testing can only be performed with cultured isolates which, for C. trachomatis, are a rare commodity in the current diagnostic environment. Whilst molecular detection of known markers associated with antimicrobial resistance can infer genotypic susceptibility, emerging resistance can only be detected through in vitro susceptibility testing. Therefore access to isolates of clinically significant pathogens, such as C. trachomatis, is imperative.
For many organisms, such as Neisseria gonorrhoeae, there are internationally recognized standard protocols for antimicrobial susceptibility testing. No such standardization exists for C. trachomatis 18 and antimicrobial susceptibility testing is particularly complex as it is an obligate intracellular organism requiring tissue cell culture for in vitro growth. 18 This, combined with the biphasic nature of the C. trachomatis lifecycle (where the extracellular phase is non-replicative), introduces a potential for assay variability not seen for other organisms. Suchland et al. 22 and Wang et al. 18 described a range of factors that may influence the MICs for C. trachomatis in vitro, such as cell line used, inoculum size and time from when infection occurs to addition of the antimicrobial. Interpretation of the endpoint of the MIC assay can also be problematic. Traditionally, immunofluorescent staining of tissue cultures has been commonly used to identify aberrant chlamydial inclusions, but this method is time-consuming and subjective. In addition, failure to visualize C. trachomatis inclusions in in vitro cultures does not exclude a viable state that can proliferate once the antibiotic pressure has been removed. 27 To negate subjectivity and to detect all viable organisms, we adapted a method previously described by Storm et al., 23 which monitored the presence of mRNA transcripts in pre-and postantimicrobial treated C. trachomatis cultures. Whilst the efficiency of reverse transcriptase PCR is known to be variable, the reproducibility of the MICs presented in this report indicate that this procedure was standardized as much as possible. The Storm assay was adapted to include detection of a predicted virulence factor gene on the C. trachomatis cryptic plasmid in place of the original C. trachomatis omp2 gene. The cryptic plasmid is constitutively expressed throughout the C. trachomatis life cycle and, whilst the number of copies of the plasmid carried can vary between different strains of C. trachomatis, 28 isolates were compared with themselves only. It was assumed that the plasmid copy number remained stable within a strain; however, it is possible that they may vary during different life cycle stages and/or when challenged with antimicrobial; investigation of this was beyond the scope of this study but is a recognized potential limitation. We also increased the time that infected cultures were incubated prior to application of the antimicrobials from 2 h, as described in Storm et al., 23 to 4 h to allow infections to establish more completely before challenge. Clean cell lines were screened for the presence of contaminants prior to inoculation as part of routine tissue culture maintenance and all infected cell line work was carried out in the presence of multiple antimicrobial/antifungal agents. However, as the isolates were clinical in origin it cannot be fully excluded that no other organism was present in the tissue culture at the time of susceptibility testing.
Despite development of a reproducible assay, there are limitations to this work. Interpretation of our MIC results was difficult as no susceptibility or resistance breakpoints exist for C. trachomatis and there are very limited data 29, 30 regarding the wild-type distributions of susceptibility to azithromycin and doxycycline for circulating strains. Owing to the dearth of susceptibility data for this organism, how in vitro MICs correlate with treatment success or failure in the patient is poorly understood. Indeed, when the results presented in this report are taken into account i.e. evidence of consistent in vivo phenotypic resistance to azithromycin in the patients persistently infected with C. trachomatis without evidence of reduced susceptibility of the isolate in vitro, the picture becomes even more complex.
Given the move to the use of doxycycline as the preferred firstline therapy for non-gonococcal urethritis, in which C. trachomatis is the most commonly identified pathogen, 31 understanding the relevance of the raised doxycycline MICs in isolates from the persistently infected patient group is important. Particularly as doxycycline may in the future be given as prophylaxis to men who have sex with men as pre-exposure prophylaxis (PrEP) for bacterial sexually transmitted pathogens 32 and the impact of this increased doxycycline usage on C. trachomatis MICs is unknown. The high level of assay reproducibility suggests that whilst the majority of strain MICs differed by only one doubling dilution, the difference (P "0.006) was unlikely related to the susceptibility testing methodology and an MIC shift towards less-susceptible was observed in the persistently infected patient group. However, the root cause of this shift and its impact on clinical outcome is unclear. A larger observational case control study is required to generate data to allow appropriate antimicrobial stewardship. 33 These data may strengthen the case for recommendation of a test of cure in all patient groups.
In addition, a number of physiological factors, such as the host inflammatory response, that would form part of natural infection resolution (in addition to antimicrobial therapy) and individual patient pharmacokinetics that cannot be replicated in in vitro cell culture systems must also be considered. It is therefore difficult to hypothesize how representative an MIC alone would be as a marker of likelihood of treatment success. There are also few data available regarding how in vitro culturing of isolates affects the organisms' susceptibility to antimicrobials. The patients who were persistently infected with C. trachomatis were exposed to a minimum of two rounds of antimicrobial therapy, but viable organisms remained. These patients were thought unlikely to have been reinfected, but this cannot be excluded completely. Antimicrobial susceptibility assays were carried out secondary to the primary isolation from the clinical specimen. As a result, it was necessary to re-culture each isolate from an archived aliquot. It is possible that multiple passages in tissue culture in the absence of antimicrobial challenge could have affected the MIC obtained, especially if surviving antimicrobial therapy in the patient led to a fitness cost. The authors recognize this as a weakness of the study and would recommend progressive processing through primary isolation and antimicrobial susceptibility testing to limit time in culture as an ideal. Further to this, the length, complexity and cost of the testing procedure is not amenable to large-scale phenotypic testing over a wide antibiotic concentration range. Processing of isolates from recovery from archive to obtaining MIC results took on average 15 working days. Nevertheless, we determined MICs of two therapeutically relevant antibiotics for 24 clinical C. trachomatis strains. Any large-scale antimicrobial resistance surveillance in C. trachomatis would need to take advantage of molecular techniques to screen for genetic markers of reduced susceptibility in addition to in vitro susceptibility testing if reliable indicators could be identified. Reassuringly, in a recent large-scale genome sequencing study of global C. trachomatis isolates, no known molecular markers of antimicrobial resistance were detected. 34 In summary, a reproducible method for phenotypic antimicrobial susceptibility testing of C. trachomatis has been described. The assay was employed for the analysis of a small number of clinical isolates from two groups of patients who had very different treatment outcomes. The azithromycin MICs for the majority of strains within the persistently positive group were comparable with those for strains in the successfully treated group. However, the MICs of doxycycline were higher in the persistently infected than in the successfully treated patient group. Antimicrobial susceptibility testing and interpretation of elevated MICs in C. trachomatis is extremely challenging in the absence of breakpoints. Further work to generate wild-type and treatment failure distribution data should be undertaken.
